Sign In
Buy PLRX
$1.18
+0.0200 (+1.72%)
At Close: Jun 03, 2026
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel the
Pliant Therapeutics Announces Three Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer
04:03pm, Tuesday, 31'st Oct 2023
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel the
Pliant (PLRX) Up on Success of Mid-Stage Liver Disease Study
12:02pm, Wednesday, 27'th Sep 2023
Shares of Pliant Therapeutics, Inc. PLRX gained 14.3% on Sep 26 after the company announced that its mid-stage study on lead pipeline candidate bexotegrast was successful.
Why Shares of Pliant Therapeutics Are Rising Tuesday
12:10pm, Tuesday, 26'th Sep 2023
Pliant Therapeutics is a clinical-stage biotech. The company said it has enough cash to fund operations through the second half of 2026.
Pliant Therapeutics shares surge as liver-disease treatment shows promise in clinical trial
08:09am, Tuesday, 26'th Sep 2023
Pliant Therapeutics Inc. shares PLRX, -2.86% gained 23% premarket on Tuesday after the company released results from a trial of bexotegrast, a treatment for a chronic liver disease. The trial met its
SOUTH SAN FRANCISCO, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced it will host a conference call and webcast on Tuesday, September 26, 2023 at 8:
Pliant Therapeutics: Promising Phase 2a Bexotegrast Data Unveiled
12:19pm, Friday, 11'th Aug 2023
Pliant Therapeutics is a biotech company focused on developing therapies for fibrotic diseases. The company's financials show an increase in R&D and administrative expenses, as well as a net loss, but
Pliant Therapeutics, Inc. (PLRX) Reports Q2 Loss, Misses Revenue Estimates
06:59pm, Wednesday, 09'th Aug 2023
Pliant Therapeutics, Inc. (PLRX) came out with a quarterly loss of $0.70 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compares to loss of $0.82 per share a year ago.
Pliant Therapeutics to Participate in Upcoming Investor Conferences
08:00am, Tuesday, 25'th Jul 2023
SOUTH SAN FRANCISCO, Calif., July 25, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics
Pliant Therapeutics, Inc. (PLRX) Reports Q1 Loss, Misses Revenue Estimates
07:06pm, Tuesday, 09'th May 2023
Pliant Therapeutics, Inc. (PLRX) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to loss of $0.78 per share a year ago.
Pliant Therapeutics: A Breath Of Fresh Air For A Multibillion Dollar IPF Market
07:55am, Saturday, 15'th Apr 2023
Pliant Therapeutics: A Breath Of Fresh Air For A Multibillion Dollar IPF Market
7 Biotech Stocks to Buy for 100% Returns
01:19pm, Sunday, 09'th Apr 2023
Generally speaking, biotech stocks to buy offer investors an excellent opportunity for significant upside success. According to Grand View Research, the global market size for the industry reached $1.
Pliant Therapeutics, Inc. (PLRX) Reports Q4 Loss, Tops Revenue Estimates
07:49pm, Thursday, 09'th Mar 2023
Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of -2.86% and 27.10%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the
Pliant Therapeutics' Bexotegrast Shows Promise For Idiopathic Pulmonary Fibrosis
10:48am, Friday, 03'rd Mar 2023
Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for fibrosis, inflammation, and related diseases. Its lead drug, bexotegrast, is being deve
Why Pliant Therapeutics Stock Is Skyrocketing This Week
04:16pm, Thursday, 26'th Jan 2023
The company's experimental idiopathic pulmonary fibrosis drug is showing a lot of promise.
